<DOC>
	<DOCNO>NCT01442974</DOCNO>
	<brief_summary>Targeting tumor stroma emerge strategic approach pancreatic cancer treatment . Actually , one interesting characteristic pancreatic cancer dense fibrotic stroma surround tumor cell . Moreover , pancreatic cancer stroma seem express specific protein profile different tumor cell . For example , secrete protein rich cysteine ( SPARC ) overexpressed pancreatic tumor stroma fibroblast downregulated tumor cell . This characteristic associate poor clinical outcome . Nab-paclitaxel , albumin bound nano formulation paclitaxel target SPARC , decrease tumor stroma density . Such effect improve drug delivery , enhances , nab-paclitaxel gemcitabine , antitumor activity nude mouse model . Based pre-clinical data investigator design clinical trial nab-paclitaxel combination gemcitabine neo-adjuvant treatment pancreatic cancer patient . Fifteen , SPARC positive patient , enrol study treat abraxane combination gemcitabine . This pilot study primary end point evaluate effect Abraxane combination gemcitabine tumor stroma , secondary end-point correlate change treatment activity .</brief_summary>
	<brief_title>Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer</brief_title>
	<detailed_description>Study Phase : Pilot study ass nab-paclitaxel combination gemcitabine effect pancreatic cancer stroma tumor metabolism . Study Objective ( ) : A ) Primary end-points : 1 . Evaluate effect nab-paclitaxel combination gemcitabine tumor stroma density . 2 . Evaluate effect nab-paclitaxel tumor vessel formation . 3 . Evaluate effect nab-paclitaxel tumor metabolism . B ) Secondary end-point : 1 . Evaluate combination activity relation change tumor stroma tumor metabolic activity . The following study perform prior treatment administration : - 18FDG-PET/CT scan ; - Ultrasound Elastography ; - IHC : 1 . SPARC ; 2 . Microvessel Density ( CD-31 , VEGF-A ) ; 3 . Stroma density ( SMA Collagen I ) . Study population Number subject : A total 15 pancreatic cancer patient resectable/resectable borderline disease expect enrol . Study design schedule : This pilot study evaluate effect nab-paclitaxel tumor stroma pancreatic cancer patient . The study conduct two part : Part A : Patients diagnose resectable/resectable pancreatic cancer screen SPARC expression . Fifteen , SPARC positive patient , enrol study treat nab-paclitaxel combination gemcitabine . Patients treat follow : - nab-paclitaxel administered 125 mg/m2 intravenous ( i.v . ) infusion 30 minute ; - follow gemcitabine 1000 mg/m2 i.v . infusion 30 minute ; Treatment deliver weekly , 3 week ( day 1 , 8 , 15 28 day cycle ) follow week rest , two cycle treatment . Part B : At end treatment tumor surgically resect accord standard surgical procedure treatment pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients 18 year old ; Patients resectable/resectable borderline pancreatic cancer ; Adequate hematopoietic , hepatic renal function : Neutrophil count &gt; = 1.5 x 109/L ; Platelet count &gt; = 100 x 109/L ; Bilirubin ≤ 1.5 x ULN ; AST and/or ALT ≤ 2.5 x ULN ; Serum creatinine ≤ 1.5 x ULN . Investigators must ensure patient enrol study available study procedure , include tumor biopsy , surgical treatment , follow . Investigators must ensure patient ability understand requirement study provide sign informed consent . Signed Informed Consent . Active uncontrolled infection serious illness medical condition could interfere patient eligibility treatment ; History psychiatric condition might impair patient 's ability understand comply requirement study provide informed consent ; Concurrent anticancer therapy ; Pregnant breastfeed woman ( document method birth control require reproductive potential ) ; History allergic reaction attribute compound similar chemical biologic composition study drug ; History life threaten reaction gemcitabine abraxane ; Previous exposure agent treatment procedure radiotherapy treatment pancreatic cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>nab-paclitaxel</keyword>
	<keyword>neoadjuvant treatment</keyword>
	<keyword>SPARC</keyword>
	<keyword>Pancreatic Cancer</keyword>
</DOC>